|M21228||WF-47-JS03||WF-47-JS03 is a potent and selective RET kinase inhibitor with more than 500-fold selectivity for the kinase insertion domain receptor (KDR).WF-47-JS03 acts on Ba/F3 cells transfected with KIF5B-RET and LC-2/ad lung cancer cells transfected with CCDC6-RET with IC50s of 1.7 nM and 5.3 nM, respectively. crossed the blood-brain barrier.|
|M10375||AD80||AD80 is a multikinase inhibitor, it potently targets human RET, BRAF, S6K, and SRC.|
|M9900||Selpercatinib (LOXO-292)||Selpercatinib (LOXO-292) is a first-in-class, highly selective and potent small molecule RET inhibitor with good blood-brain barrier (BBB) penetration. and RET (G810R) with IC50 values of 14.0 nM, 24.1 nM and 530.7 nM, respectively.|
|M9346||Pralsetinib||Pralsetinib (BLU-667) is a next generation highly potent, selective RET inhibitor with IC50 of 0.3-0.4 nM for WT RET, RET mutants V804L, V804M, M918T and CCDC6-RET fusion.|
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2020 AbMole BioScience. All Rights Reserved.